Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Biohaven starts Phase III trial of spinocerebellar ataxia drug

Spinocerebellar ataxia is a rare, potentially fatal neurodegenerative disorder. Credit: Gerd Altmann from Pixabay.



  • Biohaven starts Phase III trial of spinocerebellar ataxia drug

Go Top